{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:58:18Z","timestamp":1783576698300,"version":"3.55.0"},"reference-count":50,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.2967\/jnumed.125.270703","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T20:25:15Z","timestamp":1763670315000},"page":"105-112","source":"Crossref","is-referenced-by-count":4,"title":["First-in-Human PET Imaging of Prostate Cancer Using [\n                    <sup>68<\/sup>\n                    Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [\n                    <sup>68<\/sup>\n                    Ga]Ga-AZ-NI-093"],"prefix":"10.2967","volume":"67","author":[{"given":"Guochang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2026010206300912000_67.1.105.1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10661"},{"key":"2026010206300912000_67.1.105.2","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263262"},{"key":"2026010206300912000_67.1.105.4","doi-asserted-by":"publisher","DOI":"10.1007\/S00259-024-06857-W"},{"key":"2026010206300912000_67.1.105.5","first-page":"13N","article-title":"FDA approves Pluvicto\/Locametz for metastatic castration-resistant prostate cancer","volume":"63","year":"2022","journal-title":"J Nucl Med."},{"key":"2026010206300912000_67.1.105.6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40291-021-00548-0","article-title":"Piflufolastat F 18: diagnostic first approval","volume":"25","author":"Keam","year":"2021","journal-title":"Mol Diagn Ther."},{"key":"2026010206300912000_67.1.105.7","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-023-00665-y"},{"key":"2026010206300912000_67.1.105.8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 vipivotide tetraxetan: first approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol Diagn Ther."},{"key":"2026010206300912000_67.1.105.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.004"},{"key":"2026010206300912000_67.1.105.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf4405"},{"key":"2026010206300912000_67.1.105.11","doi-asserted-by":"publisher","DOI":"10.1038\/S41588-018-0318-2"},{"key":"2026010206300912000_67.1.105.12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.trecan.2016.05.006","article-title":"Hypoxia: signaling the metastatic cascade","volume":"2","author":"Rankin","year":"2016","journal-title":"Trends Cancer."},{"key":"2026010206300912000_67.1.105.13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96268"},{"key":"2026010206300912000_67.1.105.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07411-7"},{"key":"2026010206300912000_67.1.105.15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/acs.bioconjchem.8b00767","article-title":"Synthesis and evaluation of multifunctional fluorescent inhibitors with synergistic interaction of prostate-specific membrane antigen and hypoxia for prostate cancer","volume":"30","author":"Kwon","year":"2019","journal-title":"Bioconjug Chem."},{"key":"2026010206300912000_67.1.105.16","doi-asserted-by":"crossref","first-page":"112099","DOI":"10.1016\/j.ejmech.2020.112099","article-title":"Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties","volume":"189","author":"Kwon","year":"2020","journal-title":"Eur J Med Chem."},{"key":"2026010206300912000_67.1.105.17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.12.007","article-title":"Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor","volume":"59","author":"Zha","year":"2018","journal-title":"Nucl Med Biol."},{"key":"2026010206300912000_67.1.105.18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s11307-019-01421-7","article-title":"[68Ga]Ga-P16-093 as a PSMA-targeted PET radiopharmaceutical for detection of cancer: initial evaluation and comparison with [68Ga]Ga-PSMA-11 in prostate cancer patients presenting with biochemical recurrence","volume":"22","author":"Green","year":"2020","journal-title":"Mol Imaging Biol."},{"key":"2026010206300912000_67.1.105.19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00259-021-05539-1","article-title":"Head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/RLU.0000000000004566","article-title":"Head-to-head comparison of 68Ga-P16-093 and 68Ga-PSMA-617 PET\/CT in patients with primary prostate cancer: a pilot study","volume":"48","author":"Wang","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2026010206300912000_67.1.105.21","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s00259-023-06283-4","article-title":"A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET\/CT in patients with primary prostate cancer","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.22","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00259-024-06596-y","article-title":"First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients","volume":"51","author":"Zhao","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.23","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1007\/s00259-024-06624-x","article-title":"Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa)","volume":"51","author":"Zhao","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.24","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1021\/acs.molpharmaceut.4c00020","article-title":"Novel [68Ga\/177Lu]Ga\/Lu-AZ-093 as PSMA-targeting agent for diagnosis and radiotherapy","volume":"21","author":"Wang","year":"2024","journal-title":"Mol Pharm."},{"key":"2026010206300912000_67.1.105.25","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1021\/acs.jmedchem.4c01420","article-title":"68Ga\/177Lu-labeled bivalent agents for targeting hypoxia and PSMA-binding in prostate cancer","volume":"67","author":"Luo","year":"2024","journal-title":"J Med Chem."},{"key":"2026010206300912000_67.1.105.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026010206300912000_67.1.105.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263448"},{"key":"2026010206300912000_67.1.105.28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol."},{"key":"2026010206300912000_67.1.105.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266940"},{"key":"2026010206300912000_67.1.105.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1846-5"},{"key":"2026010206300912000_67.1.105.31","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s11307-022-01720-6","article-title":"Preliminary evaluation of 68Ga-P16-093, a PET radiotracer targeting prostate-specific membrane antigen in prostate cancer","volume":"24","author":"Lee","year":"2022","journal-title":"Mol Imaging Biol."},{"key":"2026010206300912000_67.1.105.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3419-0"},{"key":"2026010206300912000_67.1.105.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.161299"},{"key":"2026010206300912000_67.1.105.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-2043"},{"key":"2026010206300912000_67.1.105.35","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.ijrobp.2018.02.170","article-title":"The Effect of neoadjuvant androgen deprivation therapy on tumor hypoxia in high-grade prostate cancer: an 18F-MISO PET-MRI study","volume":"102","author":"Mainta","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026010206300912000_67.1.105.36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262552"},{"key":"2026010206300912000_67.1.105.37","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026010206300912000_67.1.105.38","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/thno.93249","article-title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer\u2014from bench to bedside","volume":"14","author":"Arbuznikova","year":"2024","journal-title":"Theranostics."},{"key":"2026010206300912000_67.1.105.39","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026010206300912000_67.1.105.40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","article-title":"First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Zang","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.41","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","article-title":"Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC","volume":"48","author":"Kramer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.42","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","article-title":"A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer","volume":"51","author":"Zang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.43","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1007\/s00259-024-06721-x","article-title":"Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study","volume":"51","author":"Li","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.44","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00259-025-07102-8","article-title":"Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer","volume":"52","author":"Ritt","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300912000_67.1.105.45","doi-asserted-by":"crossref","first-page":"e240080","DOI":"10.1148\/rg.240080","article-title":"PSMA radiotheranostics in prostate cancer: principles, practice, and future prospects","volume":"44","author":"Szidonya","year":"2024","journal-title":"Radiographics."},{"key":"2026010206300912000_67.1.105.46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.246041"},{"key":"2026010206300912000_67.1.105.47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007354"},{"key":"2026010206300912000_67.1.105.48","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026010206300912000_67.1.105.49","doi-asserted-by":"crossref","first-page":"101905","DOI":"10.1016\/j.redox.2021.101905","article-title":"Identification of proteins and cellular pathways targeted by 2-nitroimidazole hypoxic cytotoxins","volume":"41","author":"Rashed","year":"2021","journal-title":"Redox Biol."},{"key":"2026010206300912000_67.1.105.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267775"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:31:10Z","timestamp":1767364270000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.2967\/jnumed.125.270703"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270703","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}